AstraZeneca to take companion Dx into respiratory and heart disease
This article was originally published in Clinica
Executive Summary
The overwhelming majority of currently approved companion diagnostics are for oncology indications, but AstraZeneca wants to change all that and has signed to deals aimed at bringing companion diagnostics to respiratory disorders and heart disease.